JAK2 Monoclonal Antibody
Shipped with Ice Packs 
In Stock 
Description
Introduction to JAK2 and Monoclonal Antibodies
JAK2 is a tyrosine kinase involved in signaling through cytokine receptors (e.g., erythropoietin, thrombopoietin). Mutations such as JAK2 V617F drive myeloproliferative neoplasms (MPNs) like myelofibrosis and polycythemia vera . Monoclonal antibodies are engineered to bind specific epitopes of JAK2, enabling precise detection or neutralization.
Key Features:
-
Specificity: Engineered to avoid cross-reactivity with JAK1, JAK3, or Tyk2 .
-
Applications: Western blot (WB), immunofluorescence (IF), immunoprecipitation (IP), and immunohistochemistry (IHC) .
-
Therapeutic Potential: Targeting mutant JAK2 (e.g., JAK2 V617F) in MPNs .
Applications in Research and Diagnostics
JAK2 monoclonal antibodies are widely used to study JAK2 expression, phosphorylation, and signaling pathways.
Table 1: Key Applications
Notable Research Findings:
-
Rheumatoid Arthritis: JAK2 expression is elevated in inflammatory cells (macrophages, neutrophils) and mast cells in rat adjuvant-induced arthritis models .
-
Cancer Biology: JAK2 antibodies confirm JAK2 overexpression in myeloid malignancies and its role in STAT5 activation .
Key JAK2 Monoclonal Antibodies
Several antibodies are validated for research, each with distinct characteristics.
Therapeutic Potential and Clinical Relevance
While JAK2 inhibitors (e.g., ruxolitinib) dominate MPN treatment, monoclonal antibodies offer complementary mechanisms:
Mechanisms of Action:
-
Targeted Depletion: Antibodies bind mutant JAK2 (e.g., JAK2 V617F), inducing apoptosis in neoplastic cells .
-
Immune Modulation: Enhance anti-tumor immunity by blocking PD-L1 expression on MPN cells .
Clinical Insights:
-
Myelofibrosis: A novel monoclonal antibody (preclinical) reduces CALR-mutant cells and improves splenomegaly .
-
MPNs: Deleting JAK2 V617F via dual-recombinase systems depletes mutant hematopoietic stem cells, prolonging survival .
Limitations:
-
Cross-Reactivity: Early antibodies risk binding non-JAK2 kinases (e.g., JAK1) .
-
Delivery Challenges: Systemic administration required for hematologic malignancies.
Challenges and Future Directions
Challenges:
-
Specificity: Avoiding off-target effects on JAK1/3 or other kinases .
-
Resistance: Chronic JAK inhibitor use may select for persistent clones .
Future Directions:
Product Specs
Buffer
PBS, pH 7.4, containing 0.02% sodium azide as preservative and 50% glycerol.
Form
Liquid
Lead Time
Typically, we can ship products within 1-3 business days of receiving your order. Delivery times may vary based on shipping method and destination. Please consult your local distributor for specific delivery information.
Synonyms
JAK 2 antibody; JAK-2 antibody; JAK2 antibody; JAK2_HUMAN antibody; Janus Activating Kinase 2 antibody; Janus kinase 2 (a protein tyrosine kinase) antibody; Janus kinase 2 antibody; JTK 10 antibody; JTK10 antibody; kinase Jak2 antibody; OTTHUMP00000043260 antibody; THCYT3 antibody; Tyrosine protein kinase JAK2 antibody; Tyrosine-protein kinase JAK2 antibody
Uniprot No.
Target Background
Function
JAK2 (Janus kinase 2) is a non-receptor tyrosine kinase that plays a crucial role in various cellular processes, including growth, development, differentiation, and histone modifications. It mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, JAK2 is involved in signal transduction by associating with type I receptors, such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), and thrombopoietin (THPO), as well as type II receptors, including IFN-alpha, IFN-beta, IFN-gamma, and multiple interleukins. Following ligand binding to cell surface receptors, JAK2 phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs (signal transducer and activator of transcription) proteins. Subsequently, JAK2 phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimers or heterodimers and translocate to the nucleus to activate gene transcription. For instance, during erythropoiesis, cell stimulation with erythropoietin (EPO) leads to JAK2 autophosphorylation, activation, and its association with the erythropoietin receptor (EPOR), which becomes phosphorylated in its cytoplasmic domain. Subsequently, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated, and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. JAK2 also participates in a signaling cascade activated by increased cellular retinol, leading to the activation of STAT5 (STAT5A or STAT5B). Additionally, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. It plays a role in the cell cycle by phosphorylating CDKN1B. JAK2 cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. Within the nucleus, JAK2 plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.
Gene References Into Functions
- Clonal analysis reveals that the dominant JAK2 V617F-positive clone in Polycythemia Vera harbors EGFR C329R substitution, suggesting this mutation may contribute to clonal expansion. PMID: 28550306
- Patients with CALR mutation exhibited significantly higher concentrations of PDGF-BB and lower concentrations of SDF-1alpha compared to patients with JAK2V617F mutation. The elevated PDGF-BB and reduced SDF-1alpha levels in CALR(+) ET patients might indicate a role of these chemokines in the disturbed Ca2+ metabolism in platelets. PMID: 29390868
- This research presents two crystal structures of the human JAK2 FERM and SH2 domains bound to Leptin receptor (LEPR) and Erythropoietin receptor (EPOR), identifying a novel dimeric conformation for JAK2. PMID: 30044226
- This study investigates the pathogenesis mechanism of JAK2 F556V mutation in the MPNs. PMID: 29842959
- Mir-204 attenuates angiogenesis in lung adenocarcinoma via the JAK2-STAT3 pathway. PMID: 29281186
- FEZF1-AS1 acts as an oncogenic lncRNA in human hepatocellular carcinoma by promoting JAK2/STAT3 signaling-mediated epithelial mesenchymal transformation. PMID: 29957463
- Case Reports/Review: JAK2 mutation-associated cerebral arterial infarction and cerebral and systemic venous thromboembolism. PMID: 30056970
- HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. PMID: 29650953
- This study suggests that the JAK2V617F mutation may increase the risk of thrombosis in chronic myeloproliferative neoplasms. PMID: 30004057
- Progression to polycythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. PMID: 29368262
- JAK2 and STAT3 are activated in Idiopathic pulmonary fibrosis. PMID: 29409529
- The prevalence of CALR mutation in JAK2V617F-negative essential thrombocythemia in this study is 35.7%. HRM is an effective method of detecting CALR mutation and is a more advantageous method of screening for CALR mutation. PMID: 29521158
- Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms based on causal biological mechanisms. Mutations in JAK2, CALR, or MPL are the sole abnormality in 45% of the patients. PMID: 30304655
- Findings outlined in this study demonstrate that the inhibition of P16 decreased the growth and metastasis potential of BC cells by inhibiting IL-6/JAK2/STAT3 signaling. PMID: 29388151
- MPL-mutated and CALR-mutated essential thrombocythaemia share clinical and histological characteristics, with both genotypes showing higher platelet counts and marked megakaryocytic proliferation compared to JAK2V617F-mutated ET. PMID: 29934356
- Results presented here provide insights into understanding how the JAK2 V625F mutation causes myeloproliferative neoplasms and offer information for the development of JAK2 mutation-specific inhibitors. PMID: 29782975
- Concomitant presence of JAK2V617F mutation and BCRABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms. PMID: 29845291
- The JAK2 V617F mutation and thrombocytopenia. PMID: 27614229
- PBX1 plays an oncogenic role in clear cell renal carcinoma via the JAK2/STAT3 pathway. PMID: 29678569
- This study shows that JAK2V617F leads to abnormal expression of numerous proteins at the membrane of circulating PV red blood cells, with overexpression of CALR and persistence of CANX. PMID: 28385780
- In 94.9% of PV, 85.5% ET, and 85.2% PMF, authors found mutations in JAK2, MPL, or CALR. 74.9% carried JAK2V617F, 12.3% CALR mutations, 2.1% MPL mutations, and 10.7% were triple negative. PMID: 28990497
- Tyrphostin B42 induced apoptosis of pancreatic cancer cells (PCCs) by regulating the expression of mitochondrial-related genes. Therefore, these findings demonstrated that tyrphostin B42 attenuated trichostatin A resistance in PCCs by antagonizing the IL6/JAK2/STAT3 signaling. PMID: 29393444
- MiR-375 inhibits fetal ASM cell proliferation and migration by targeting the JAK2/STAT3 signaling. PMID: 29245068
- Data show that HIT is more frequent during heparin treatment in patients with ET carrying the V617F mutation compared to patients without mutations. PMID: 29022213
- Overexpression of ALK4 suppressed glioma cell proliferation, migration, and invasion through the inactivation of the JAK/STAT3 signaling pathway. PMID: 29278854
- This study describes a subset of non-small-cell lung cancer patients who had JAK2 amplifications resulting in high expression of PD-L1. PMID: 28795418
- High JAK2 expression is associated with hepatocellular carcinoma. PMID: 28677802
- JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN. PMID: 29134760
- Low JAK2 expression is associated with gastric cancer. PMID: 28656307
- Researchers discovered that tyrosine 78 of Atoh1 is phosphorylated by a Jak2-mediated pathway only in tumor-initiating cells and in human Sonic Hedgehog-type medulloblastoma. PMID: 29168692
- This study concludes that the activating JAK2 V617F mutation does not play a decisive role in the pathogenesis of progressive CKD. PMID: 27889755
- These findings revealed that B7-H3 affects ovarian cancer progression through the Jak2/Stat3 pathway, indicating that B7-H3 has the potential to be a useful prognostic marker. PMID: 28765941
- In 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease, the percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) compared to MPL- (75%) and JAKV617F-mutated patients (67%). PMID: 28714945
- Mutational subtypes of JAK2 correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. PMID: 29464483
- Identification of activating somatic mutations in JAK2 and germline mutations in JAK3 with clinical implications. PMID: 29082853
- Screening for the JAK2 V617F mutation in cerebral venous thrombosis patients seems beneficial due to its relatively high prevalence and the risk of thrombosis recurrence. PMID: 28609766
- Ascochlorin significantly decreased phosphorylation of JAK2/STAT3, cancer cell migration, and nuclear translocation of STAT3. PMID: 28569433
- TLR7, TLR9, and JAK2 genes are potential biomarkers for systemic sclerosis. High TLR7 expression positively correlated with the late form of the disease. Decreased levels of TLR9 and JAK2 mRNA were found in the patient's cohort compared to non-SSc individuals. PMID: 29147913
- This study demonstrated that the JAK2V617F mutation was detectable in patients with stroke. PMID: 28625126
- Curcumin attenuated neuropathic pain and down-regulated the production of spinal mature IL-1beta by inhibiting the aggregation of NALP1 inflammasome and the activation of the JAK2-STAT3 cascade in astrocytes. PMID: 27381056
- High levels of phosphorylated JAK2 and STAT3 are associated with systemic lupus erythematosus. PMID: 28177455
- This study shows that Nrf2 activation induces lipocyte phenotype in hepatic stellate cells via enhancing SOCS3-dependent feedback inhibition on the JAK2/STAT3 cascade. PMID: 28601022
- Bladder cancer cells may inhibit the maturation and function of dendritic cells involving the Jak2/STAT3 pathway, and there may be different mechanisms by which adriamycin-resistant BCC restrains DC function in antitumor immune response. PMID: 27556503
- Multivariate analysis adjusted for age, sex, follow-up period, and hematological parameters confirmed that increased activated B cells were universally present in JAK2-mutated, CALR-mutated, and triple-negative ET patients compared to healthy adults. PMID: 28415571
- In multivariable analysis, younger age, platelet count, hemoglobin level, and JAK2 V617F mutation independently predicted the development of acquired von Willebrand syndrome (AVWS) among essential thrombocythemia (ET) patients; whereas only platelet count predicted its development among polycythemia vera (PV) patients. Among ET patients, JAK2 V617F was a main driver for the development of AVWS. PMID: 27919526
- CXCR4 induced VEGF production and JAK2/STAT3 activation and enhanced STAT3 binding to the VEGF promoter in gastric cancer cells. PMID: 28544312
- These results reveal proteome alterations in MPN granulocytes depending on the phenotype and genotype of patients, highlighting new oncogenic mechanisms associated with JAK2 mutations and overexpression of calreticulin. PMID: 28314843
- JAK2 mutation is associated with Essential thrombocythemia. PMID: 28205126
- Considering JAK2(V617F)-positive disease, a higher (>50%) JAK2(V617F) burden and histological classification are independent prognostic risk factors for disease progression. PMID: 28509339
- Taken together, this study found that silibinin inhibits the Jak2/STAT3/MMP2 signaling pathway and inhibits the proliferation, migration, and invasion of triple-negative breast cancer cells. PMID: 28440514
Database Links
Involvement In Disease
Budd-Chiari syndrome (BDCHS); Polycythemia vera (PV); Thrombocythemia 3 (THCYT3); Myelofibrosis (MYELOF); Leukemia, acute myelogenous (AML)
Protein Families
Protein kinase superfamily, Tyr protein kinase family, JAK subfamily
Subcellular Location
Endomembrane system; Peripheral membrane protein. Cytoplasm. Nucleus.
Tissue Specificity
Ubiquitously expressed throughout most tissues.
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
